Viridian Therapeutics, Inc. VRDN Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $70.85M+23,360% | $302K-3.8% | $314K-82.3% | $1.77M-40.2% | ||
| $338.93M+42.3% | $238.26M+49.1% | $159.77M+58.3% | $100.89M+77.4% | ||
| —— | $61.08M-35.7% | $95M— | —— | ||
| $434.24M+45.1% | $299.34M+17.5% | $254.76M+87.2% | $136.08M+64.6% | ||
| -$363.4M-21.5% | -$299.04M-17.5% | -$254.45M-89.5% | -$134.3M-68.5% | ||
| -512.9%+98,506pp | -99,018.5%-17,984pp | -81,035%-73,456pp | -7,579.2%-4,888pp | ||
| $4.91M+120% | $2.23M+67.5% | $1.33M+174% | $486K+16,100% | ||
| $20.79M-28.5% | $29.09M+74.0% | $16.72M+277% | $4.43M+1,306% | ||
| -$342.6M-26.9% | -$269.95M-13.6% | -$237.73M-83.0% | -$129.87M-63.5% | ||
| -483.6%+88,904pp | -89,387.1%-13,676pp | -75,711.5%-68,382pp | -7,329.2%-4,649pp | ||
| —— | —— | -$5.31-30.5% | -$4.07+42.5% | ||
| -$362.94M-21.6% | -$298.5M-17.6% | -$253.93M-89.4% | -$134.05M-68.4% | ||
| -512.3%+98,327pp | -98,839.7%-17,971pp | -80,868.8%-73,304pp | -7,564.8%-4,878pp | ||
| -$363.4M-21.5% | -$299.04M-17.5% | -$254.45M-89.5% | -$134.3M-68.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Gross margin is 36.3% and operating margin is -543.9%, with a -508.5% net margin.
- Where does Viridian Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.